Ray Shayoni, Cekanaviciute Egle, Lima Ivan Paulino, Sørensen Brita Singers, Costes Sylvain V
USRA/NASA Ames Research Center, Moffett Field, CA, USA.
Department of Experimental Clinical Oncology, Aarhus University Hospital, Denmark.
Int J Part Ther. 2018 Summer;5(1):15-24. doi: 10.14338/IJPT-18-00018.1. Epub 2018 Sep 21.
Treatment modalities for cancer radiation therapy have become increasingly diversified given the growing number of facilities providing proton and carbon-ion therapy in addition to the more historically accepted photon therapy. An understanding of high-LET radiobiology is critical for optimization of charged particle radiation therapy and potential DNA damage response. In this review, we present a comprehensive summary and comparison of these types of therapy monitored primarily by using DNA damage biomarkers. We focus on their relative profiles of dose distribution and mechanisms of action from the level of nucleic acid to tumor cell death.
鉴于除了历史上更被认可的光子疗法外,提供质子和碳离子疗法的设施越来越多,癌症放射治疗的治疗方式日益多样化。了解高传能线密度放射生物学对于优化带电粒子放射治疗和潜在的DNA损伤反应至关重要。在本综述中,我们主要通过使用DNA损伤生物标志物,对这些治疗类型进行了全面的总结和比较。我们从核酸水平到肿瘤细胞死亡,重点关注它们相对的剂量分布概况和作用机制。